All conditions

Multiple Sclerosis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

43
Trials tracked
9
Recruiting now
38
Australian sites
63
Countries
Country

Showing 43 trials

🇦🇺 AU site

Trial: NCT06372145 — Sanofi

NCT06372145 · Sanofi
Active, Not Recruiting Phase 3 Est. completion 30 April 2029
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You have a form of multiple sclerosis (relapsing MS, primary progressive MS, or non-relapsing secondary progressive MS) and you previously completed a related earlier clinical trial (Phase 2b or...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04035005 — Hoffmann-La Roche

NCT04035005 · Hoffmann-La Roche
Active, Not Recruiting Phase 3 Est. completion 15 January 2025
🇦🇺 AU 🇧🇪 BE 🇧🇬 BG 🇨🇦 CA 🇨🇴 CO

**Who might be able to join this trial:** - Your MS disability level (measured by a standard scale called EDSS) must be between 3.0 and 8.0 at the start of the trial - How long you have had MS symptoms matters and depends on your disabilit...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05123703 — Hoffmann-La Roche

NCT05123703 · Hoffmann-La Roche
Active, Not Recruiting Phase 3 Est. completion 9 June 2025
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You weigh at least 25 kilograms (about 55 pounds) - You have been diagnosed with relapsing-remitting multiple sclerosis (RRMS) according to specific recognized medical guidelines for children and...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04926818 — Novartis Pharmaceuticals

NCT04926818 · Novartis Pharmaceuticals
Active, Not Recruiting Phase 3 Est. completion 25 March 2026
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

Who might be able to join this trial: - You are between 10 and 17 years old (must not have turned 18 yet at the time of joining the trial) - You have been diagnosed with multiple sclerosis (MS) - Your MS disability level falls within a cert...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01285479 — Novartis Pharmaceuticals

NCT01285479 · Novartis Pharmaceuticals
Completed Not Applicable Est. completion 29 May 2024
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

Who might be able to join this trial: - You are a woman who has been diagnosed with Multiple Sclerosis (MS) - You are currently pregnant - You were taking a medication called fingolimod either during your pregnancy or up to 8 weeks before y...

🇦🇺 AU site

Trial: NCT01526356 — The University of Texas Health Science Center, Houston

NCT01526356 · The University of Texas Health Science Center, Hou...
Completed Phase 2 Est. completion 1 August 2014
🇦🇺 AU 🇺🇸 US

**Who might be able to join this trial:** - You must be willing and able to follow all the rules and requirements of the trial. - You have been diagnosed with Tuberous Sclerosis Complex (TSC) and have visible small skin growths on your face...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05364021 — Longboard Pharmaceuticals

NCT05364021 · Longboard Pharmaceuticals
Completed Phase 2 Est. completion 16 November 2023
🇦🇺 AU 🇺🇸 US

Who might be able to join this trial: - You are male, or female and not currently pregnant or breastfeeding, and are between 12 and 65 years old - You have been diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, or another similar con...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04676555 — Novartis Pharmaceuticals

NCT04676555 · Novartis Pharmaceuticals
Completed Not Applicable Est. completion 21 October 2021
🇦🇺 AU 🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a form of multiple sclerosis called relapsing MS (this includes clinically isolated syndrome/CIS, relapsing-remitting MS/RRMS, or ac...

🇦🇺 AU site

Trial: NCT00404352 — Merck KGaA, Darmstadt, Germany

NCT00404352 · Merck KGaA, Darmstadt, Germany
Completed Phase 3 Est. completion 1 August 2010
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇬 BG

**Who might be able to join this trial:** - You had your first episode of possible MS symptoms within the last 60 days, lasting at least 24 hours, involving neurological changes (not just tingling sensations, bladder/bowel issues, or think...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00355134 — Novartis

NCT00355134 · Novartis
Completed Phase 3 Est. completion 1 June 2011
🇦🇺 AU 🇦🇹 AT 🇨🇦 CA 🇵🇱 PL 🇷🇴 RO

**Who might be able to join this trial:** - You are a man or woman between the ages of 18 and 55 who has been diagnosed with multiple sclerosis - Your multiple sclerosis follows a relapsing-remitting pattern, meaning you have flare-ups foll...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05826028 — Novartis Pharmaceuticals

NCT05826028 · Novartis Pharmaceuticals
Completed Not Applicable Est. completion 20 April 2022
🇦🇺 AU

Who might be able to join this trial: - You are an adult who has been diagnosed with secondary progressive multiple sclerosis (a form of MS that gradually gets worse over time), as confirmed by your doctor. - Your level of physical disabili...

🇦🇺 AU site

Trial: NCT00493298 — Biogen

NCT00493298 · Biogen
Completed Not Applicable Est. completion 1 November 2023
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

Who might be able to join this trial: - You must have been diagnosed with Relapsing Remitting Multiple Sclerosis (a form of MS where symptoms come and go in episodes) - Your doctor must have already decided that Tysabri (a specific MS medic...

🇦🇺 AU site

Trial: NCT01247324 — Hoffmann-La Roche

NCT01247324 · Hoffmann-La Roche
Completed Phase 3 Est. completion 2 April 2015
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed with multiple sclerosis (MS), confirmed using the 2010 McDonald criteria - You have had at least 2 MS attacks (relapses) in the last 2 years before screening, OR at least 1...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04353492 — Novartis Pharmaceuticals

NCT04353492 · Novartis Pharmaceuticals
Completed Phase 3 Est. completion 9 October 2024
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇬 BG

**Who might be able to join this trial:** - You have been diagnosed with multiple sclerosis (MS) according to a specific set of recognised diagnostic guidelines (the 2017 McDonald criteria) - You have a relapsing form of MS, which includes...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03650452 — Takeda

NCT03650452 · Takeda
Completed Phase 2 Est. completion 9 June 2020
🇦🇺 AU 🇨🇦 CA 🇨🇳 CN 🇮🇱 IL 🇵🇱 PL

**Who might be able to join this trial:** - Children and teenagers between 2 and 17 years old (both boys and girls) - Have been diagnosed with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) - Weigh at least 10 kilograms (about 22 pou...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05626634 — Longboard Pharmaceuticals

NCT05626634 · Longboard Pharmaceuticals
Completed Phase 2 Est. completion 20 December 2024
🇦🇺 AU 🇺🇸 US

Who might be able to join this trial: - You are male, or female and not currently pregnant or breastfeeding, and are between 12 and 65 years old, and have already completed the related study called LP352-201 - You have been diagnosed with D...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01194570 — Hoffmann-La Roche

NCT01194570 · Hoffmann-La Roche
Completed Phase 3 Est. completion 23 July 2015
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR 🇧🇬 BG

**Who might be able to join this trial:** - You have been diagnosed with primary progressive multiple sclerosis (PPMS), confirmed using specific medical guidelines called the revised McDonald criteria - Your level of physical disability, me...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02544763 — Jazz Pharmaceuticals

NCT02544763 · Jazz Pharmaceuticals
Completed Phase 3 Est. completion 22 January 2019
🇦🇺 AU 🇳🇱 NL 🇵🇱 PL 🇪🇸 ES 🇬🇧 GB

**Who might be able to join this trial:** - You have a well-documented medical history of epilepsy (seizures). - You have been diagnosed with Tuberous Sclerosis Complex (TSC) based on the internationally agreed 2012 diagnostic guidelines. -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT01281189 — Knopp Biosciences

NCT01281189 · Knopp Biosciences
Completed Phase 3 Est. completion 1 November 2012
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE

Who might be able to join this trial: - You must be between 18 and 80 years old at the start of the trial. - You must have been diagnosed with ALS, either the sporadic (no family history) or familial (runs in the family) type. - Your first...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02870634 — Collaborative Medicinal Development Pty Limited

NCT02870634 · Collaborative Medicinal Development Pty Limited
Completed Phase 1 Est. completion 30 October 2019
🇦🇺 AU

**Who might be able to join this trial:** - You have signed a consent form before any study procedures begin - You have been diagnosed with ALS (also called Motor Neurone Disease), whether inherited or not, at any stage from "possible" to...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05882695 — Spinogenix

NCT05882695 · Spinogenix
Completed Phase 1 Est. completion 27 June 2025
🇦🇺 AU

Who might be able to join this trial: **General (Healthy Volunteer) Group:** - You are between 18 and 55 years old - You are in good general health with no significant medical history - Your routine blood and lab test results are within no...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00930553 — Genzyme, a Sanofi Company

NCT00930553 · Genzyme, a Sanofi Company
Completed Phase 3 Est. completion 1 February 2016
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You took part in a previous related study called CAMMS323 or CAMMS324, received the drug alemtuzumab, completed the full 2-year study, and did not go on to take other MS treatments afterward (exc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT00622700 — Sanofi

NCT00622700 · Sanofi
Completed Phase 3 Est. completion 1 December 2012
🇦🇺 AU 🇦🇹 AT 🇧🇬 BG 🇨🇦 CA 🇨🇱 CL

Who might be able to join this trial: - You have had your first clear neurological episode (such as optic neuritis diagnosed by an eye doctor, problems with your spinal cord, or issues with balance/coordination) that doctors believe may be...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04676204 — Monash University

NCT04676204 · Monash University
By Invitation Not Applicable Est. completion 19 November 2025
🇦🇺 AU

Who might be able to join this trial: - You are 18 years old or older. - You have been officially diagnosed with multiple sclerosis. - You have recently started (either as a new prescription or by switching) one of these six specific MS med...

🇦🇺 AU site

Trial: NCT07224373 — AstraZeneca

NCT07224373 · AstraZeneca
Recruiting Phase 1 Est. completion 7 December 2028
🇦🇺 AU 🇨🇦 CA 🇩🇪 DE 🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 60 years old at the time of signing the consent form - You are able and willing to give written consent to take part in the study - Your overall physical health and body fu...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06675864 — Novartis Pharmaceuticals

NCT06675864 · Novartis Pharmaceuticals
Recruiting Phase 2 Est. completion 14 June 2030
🇦🇺 AU 🇨🇦 CA 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT

**Who might be able to join this trial:** - You are between 18 and 60 years old (inclusive) at the time of screening - You are willing and able to sign a consent form before the study begins - You are able to communicate clearly with the s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06351592 — Regeneron Pharmaceuticals

NCT06351592 · Regeneron Pharmaceuticals
Recruiting Phase 2 Est. completion 21 March 2032
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇯🇵 JP 🇰🇷 KR

**Who might be able to join this trial:** - You have muscle weakness caused by ALS, and genetic testing has shown you carry a change in the SOD1 gene that is known or likely to cause ALS - Your lungs are working at 50% or more of the expect...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07295847 — AstraZeneca

NCT07295847 · AstraZeneca
Recruiting Phase 1 Est. completion 22 February 2028
🇦🇺 AU 🇩🇪 DE 🇪🇸 ES 🇬🇧 GB 🇺🇸 US

**Who might be able to join this trial:** - You are able to understand and sign a consent form agreeing to take part - Your overall physical health and body function are considered adequate at the start of the study - You are willing and a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT07282574 — Hoffmann-La Roche

NCT07282574 · Hoffmann-La Roche
Recruiting Phase 2 Est. completion 30 May 2028
🇦🇺 AU 🇫🇷 FR 🇩🇪 DE 🇭🇺 HU 🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with Progressive Multiple Sclerosis (MS), confirmed using a specific set of medical guidelines called the 2017 McDonald criteria - Your level of physical disability, as mea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT05658497 — Biogen

NCT05658497 · Biogen
Recruiting Not Applicable Est. completion 6 July 2032
🇦🇺 AU 🇩🇪 DE 🇮🇪 IE 🇪🇸 ES 🇨🇭 CH

**Who might be able to join this trial:** - You have been diagnosed with Multiple Sclerosis (MS) - You were either exposed to a medication called Diroximel Fumarate (DRF) at some point from around the time of conception through any point du...

🇦🇺 AU site

Trial: NCT06846281 — Novartis Pharmaceuticals

NCT06846281 · Novartis Pharmaceuticals
Recruiting Phase 3 Est. completion 24 July 2029
🇦🇷 AR 🇦🇺 AU 🇧🇪 BE 🇧🇷 BR 🇨🇦 CA

Who might be able to join this trial: - You are between 40 and 70 years old (inclusive) - You have been diagnosed with relapsing multiple sclerosis (RMS) based on the 2017 McDonald diagnostic guidelines - You are currently being treated wit...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06617793 — Novartis Pharmaceuticals

NCT06617793 · Novartis Pharmaceuticals
Recruiting Phase 2 Est. completion 1 October 2030
🇦🇺 AU 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT 🇪🇸 ES

**Who might be able to join this trial:** - You must be willing and able to sign a consent form and communicate well with the research team throughout the study - Your kidneys, liver, heart, blood, and lungs must be functioning well enough...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT06408259 — Bristol-Myers Squibb

NCT06408259 · Bristol-Myers Squibb
Recruiting Phase 3 Est. completion 11 April 2031
🇦🇺 AU 🇮🇹 IT 🇲🇽 MX 🇵🇱 PL 🇵🇹 PT

**Who might be able to join this trial:** - You have been diagnosed with relapsing-remitting multiple sclerosis (MS), meaning your MS comes in episodes or "attacks" followed by periods of recovery, confirmed using 2017 diagnostic guidelines...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT04944784 — Cytokinetics

NCT04944784 · Cytokinetics
Terminated Phase 3 Est. completion 18 July 2023
🇦🇺 AU 🇧🇪 BE 🇨🇦 CA 🇩🇰 DK 🇫🇷 FR

Who might be able to join this trial: - You are between 18 and 80 years old (inclusive) - You have been diagnosed with familial or sporadic ALS, meeting certain diagnostic standards set by a global neurology organization (confirm with trial...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02907177 — Actelion

NCT02907177 · Actelion
Terminated Phase 3 Est. completion 26 March 2020
🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇬 BG 🇨🇦 CA

**Who might be able to join this trial:** - You must be willing to sign a consent form before any study procedures begin. - Women who could become pregnant must have a negative pregnancy test and use reliable birth control during the study....

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT03085810 — Hoffmann-La Roche

NCT03085810 · Hoffmann-La Roche
Terminated Phase 3 Est. completion 27 April 2023
🇦🇷 AR 🇦🇺 AU 🇦🇹 AT 🇧🇪 BE 🇧🇷 BR

**Who might be able to join this trial:** - You have been officially diagnosed with relapsing-remitting multiple sclerosis (RRMS) using a specific standard diagnostic method called the McDonald 2010 criteria - Your MS was first diagnosed or...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site

Trial: NCT02342704 — Biogen

NCT02342704 · Biogen
Terminated Phase 4 Est. completion 18 May 2016
🇦🇺 AU 🇨🇿 CZ 🇫🇷 FR 🇩🇪 DE 🇮🇹 IT

**Who might be able to join this trial:** *For people with Multiple Sclerosis (MS):* - You must have a confirmed diagnosis of relapsing MS, with a disability score between 0.0 and 5.5 on a standard MS scale. - If you are currently taking o...

Phase 4: Approved of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 AU site
UNKNOWN Not Applicable Est. completion 31 December 2025
🇦🇷 AR 🇦🇺 AU Botswana 🇧🇷 BR 🇨🇴 CO

Who might be able to join this trial: - You are experiencing your first-ever episode of optic neuritis (inflammation of the optic nerve) - Your vision symptoms started no more than 30 days ago - You are 18 years of age or older - You are ab...

Trial: NCT01628276 — Sina Hospital, Iran

NCT01628276 · Sina Hospital, Iran
Completed Not Applicable Est. completion 1 September 2013
Iran

Who might be able to join this trial: - You have been officially diagnosed with Multiple Sclerosis (MS) - You are right-handed - Your MS disability level falls within a certain range (scored 0 to 4 on a standard MS disability scale — confir...

Trial: NCT02695394 — Charite University, Berlin, Germany

NCT02695394 · Charite University, Berlin, Germany
Completed Not Applicable Est. completion 1 December 2016
🇩🇪 DE

Who might be able to join this trial: - You are between 18 and 85 years old - You are right-handed - For patients: You have been diagnosed with a first episode that may suggest MS (called CIS), or you have been diagnosed with MS for 5 years...

Trial: NCT01767701 — Queen Mary University of London

NCT01767701 · Queen Mary University of London
Completed Phase 2 Est. completion 1 September 2014
🇬🇧 GB

**Who might be able to join this trial:** - You are between 18 and 55 years old. - You have been diagnosed with Multiple Sclerosis (MS) according to specific 2010 diagnostic guidelines. - Your MS disability level falls within a certain ran...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT00668343 — Tehran University of Medical Sciences

NCT00668343 · Tehran University of Medical Sciences
Completed Phase 3 Est. completion 1 March 2008
Iran

Who might be able to join this trial: - Your disability level is below 5 on a standard neurological scale used to measure how much a condition affects daily functioning (confirm with trial site) - You have had at least 1 attack or flare-up...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Trial: NCT05344040 — Kessler Foundation

NCT05344040 · Kessler Foundation
Completed Early Phase 1 Est. completion 1 December 2022
🇺🇸 US

**Who might be able to join this trial:** - You must have a confirmed diagnosis of multiple sclerosis (MS). - You must not have had an MS flare-up, and must not have taken steroid medications, in the 30 days before joining the study. - You...

Early Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)